论文部分内容阅读
目的探讨普罗布考对早期糖尿病肾病患者血清脂联素和骨形态发生蛋白-7(BMP-7)的影响。方法 96例早期糖尿病肾病患者随机分为两组,治疗组50例,对照组46例;对照组采用常规治疗,治疗组在常规治疗的基础上加用普罗布考,治疗前后测定两组患者的微量白蛋白排泄率、血清脂联素和BMP-7。结果治疗组治疗前后分别为(157.6±42.8)μg/min、(72.6±20.4)μg/min,对照组治疗前后分别为(149.8±39.7)μg/min、(113.6±20.7)μg/min;两组治疗后均有明显改善,并且治疗组治疗后优于对照组(P<0.05);两组治疗后血清脂联素均明显降低,并且治疗组降低更明显(P<0.05);两组治疗后BMP-7均有明显升高,治疗组升高程度更明显(P<0.05)。结论普罗布考可以通过改善早期糖尿病肾病脂联素和BMP-7的表达,从而减少患者尿微量白蛋白排泄率。
Objective To investigate the effects of probucol on serum adiponectin and bone morphogenetic protein-7 (BMP-7) in patients with early diabetic nephropathy. Methods Ninety-six patients with early diabetic nephropathy were randomly divided into two groups: 50 cases in the treatment group and 46 cases in the control group. The control group was treated with routine therapy. The treatment group was given probucol on the basis of routine treatment. Microalbumin excretion rate, serum adiponectin and BMP-7. Results Before and after treatment, the treatment group was (157.6 ± 42.8) μg / min and (72.6 ± 20.4) μg / min respectively, while the control group was (149.8 ± 39.7) μg / min and (113.6 ± 20.7) μg / (P <0.05). The levels of serum adiponectin in both groups were significantly decreased after treatment, and the treatment group decreased more obviously (P <0.05). The two groups of treatment After BMP-7 were significantly increased, the treatment group increased more significantly (P <0.05). Conclusion Probucol can reduce the urinary albumin excretion rate of patients by improving the expression of adiponectin and BMP-7 in early diabetic nephropathy.